Lexicon’s sotagliflozin shows breakthrough potential for heart failure patients without diabetes
Lexicon Pharmaceuticals has revealed promising results from its sotagliflozin drug, which could significantly improve outcomes for heart failure patients with preserved ejection fraction (HFpEF), a condition affecting nearly 3.4 million Americans. The drug, discovered using Lexicon's unique genomics platform, the Genome5000TM program, showed substantial benefits in a recent clinical trial.
The SOTA P CARDIA trial, led by Dr. Juan J Badimon, enrolled 88 racially diverse participants, 70% female, and treated them with sotagliflozin or a placebo for six months. The results, announced at the AHA Annual Scientific Sessions 2025, were encouraging. Sotagliflozin resulted in statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test, and Kansas City Cardiomyopathy Questionnaire (KCCQ) measurements. It also showed notable improvement in peak VO2, although this did not reach statistical significance.
The trial's principal investigators, including Dr. Mikhail N. Kosiborod, Dr. Javed Butler, and Dr. Darren K. McGuire, highlighted the drug's potential in treating HFpEF patients without diabetes. This is particularly significant as current treatments for this condition are limited. Sotagliflozin's approval in 2023 for heart failure patients with or without diabetes underscores its potential to transform patient lives, aligning with Lexicon's mission.
Lexicon Pharmaceuticals' sotagliflozin has demonstrated significant improvements in various measures in HFpEF patients without diabetes. These findings, presented at the AHA Annual Scientific Sessions 2025, suggest sotagliflozin could be a valuable addition to the treatment landscape for this challenging condition.
